German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a US$3.9 billion ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a $3.9-billion ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

The global Live Cell Imaging Market, valued at US$2.88 billion in 2024, is forecasted to grow at a robust CAGR of 8.68%, ...

Frequent visitors to The Huntington will be surprised to see starkly different signage as they enter the gates. The ...